Biosimilar products (Ep. 25)
From Clinical Pharmacology Podcast with Nathan Teuscher · · 16 min
This plays from the publisher's own server. We do not host a copy.
Description
Today’s show discussed biosimilar development from a clinical pharmacology perspective. I describe what biosimilar products are and the necessary comparisons to the reference product. I review requirements for PK similarity, PD similarity, immunogenicity, and safety. I also touch on the idea of interchangeability between the biosimilar and reference products.
Links discussed in the show:
- FDA Guidance on Clinical Pharmacology Data to support Biosimilarity (https://go.teuschersolutions.com/biosim1) (May 2016)
- FDA Guidance on Demonstrating Interchangeability (https://go.teuschersolutions.com/biosim2) (May 2019)
- FDA Q&A on Biosimilarity and Interchangeability (https://go.teuschersolutions.com/biosim3) (Sep 2023)
- You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message
- Send me a message (https://go.teuschersolutions.com/contact)
- Sign up for my newsletter (https://go.teuschersolutions.com/newsletter)
Copyright Teuscher Solutions LLC
All Rights Reserved
Back to Clinical Pharmacology Podcast with Nathan Teuscher · Report a problem